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Abstract 
The aim was to determine whether fed very low density lipoprotein (VLDL) and 
chylomicron (CM) triacylglycerol (TAG) production rates are elevated in metabolic 
syndrome (MetS). Eight men with MetS (BMI 29.7± 1.1) and 8 lean age matched 
healthy men (BMI 23.1± 0.4) were studied using a frequent feeding protocol.  After 4 
hours of feeding an intravenous bolus of 2H5-glycerol was administered to label 
VLDL1, VLDL2 and CM TAG. 13C glycerol tripalmitin was administered orally as an 
independent measure of CM TAG metabolism. Hepatic and intestinal lipoproteins 
were separated by an immunoaffinity method. In MetS, fed TAG and the increment in 
TAG from fasting to feeding were higher (p=0.03, p<0.05 respectively) than in lean 
men. Fed CM, VLDL1 and VLDL2 TAG pool sizes were higher (p=0.006, p=0.03, 
p<0.02) and CM, VLDL1 and VLDL2 TAG production rates were higher (p<0.002, 
p<0.05, p=0.06) than in lean men. VLDL1, VLDL2 and CM TAG clearance rates 
were not different between groups. In conclusion prandial hypertriglyceridemia in 
men with MetS was due to an increased production rate of both VLDL and CM TAG. 
Since both groups received identical meals this suggests that in MetS the intestine is 
synthesising more TAG de novo for export in CMs. 
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Introduction 
Abnormally elevated blood triacylglycerol (TAG) levels in the postprandial period is a 
feature of MetS and is predictive of an increased risk of cardiovascular disease 
(CVD)(1,2,3). Hypertriglyceridemia is due to excess triglyceride-rich lipoproteins 
(TRL); very low-density lipoproteins, (VLDL) synthesised by the liver which contain 
the higher molecular weight form of apolipoprotein (apo)B, apoB100 and 
chylomicrons (CMs) which are synthesised in the intestine in response to an intake of 
dietary fat, which contain the lower molecular weight form of apoB, apoB48. Both 
VLDL and CMs share a common lipolytic pathway and are hydrolysed by lipoprotein 
lipase (LPL), an enzyme predominantly found on the endothelial surfaces of the 
capillaries of adipose tissue, heart and skeletal muscle (4).  
 
Postprandial hypertriglyceridemia in MetS may be due to the overproduction of 
intestinal or hepatic TRLs, impaired clearance or a combination of both. Insulin 
resistance is associated with a postprandial increase in apoB48 particles (5) and some 
studies suggested that this is due to impaired catabolism of intestinally derived TRL 
and remnant lipoprotein TAG (6,7). However the small intestine is capable of utilising 
endogenous substrates for TAG synthesis. Duez et al (8) have used a constant feeding 
protocol combined with an infusion of a labelled leucine to measure apoB48 kinetics, a 
surrogate measure of intestinal TRL kinetics, in men with a range of insulin sensitivity. 
The study showed that insulin resistance was associated with increased intestinal 
apoB48 production rate. In addition diet-induced insulin resistance in the Syrian golden 
hamster has been shown to be associated with a marked increase in intestinal 
lipoprotein production rate in both the fasting and the fed states (9) which could be 
reduced by treatment with rosiglitazone (10). Since insulin resistance is associated with 
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elevated non esterified fatty acid (NEFA) flux from adipose tissue the mechanism that 
leads to apoB48 overproduction may be increased delivery of NEFAs to the enterocyte 
since an acute elevation of NEFAs in hamsters has been shown to increase basal 
intestinal apoB48 production (11).  
 
A number of studies have shown that VLDL apoB100 and VLDL TAG production 
rate is increased by insulin resistance (12,13) in the fasted state but no studies have 
measured VLDL TAG production rate quantitatively, in the fed state, in MetS. We 
have recently demonstrated that intravenously administered 2H5 glycerol is 
incorporated into CM TAG and can be used to measure both CM and VLDL TAG 
kinetics in a frequent feeding study (14). In the present study we have used this 
methodology to investigate whether the greater increase in postprandial TAG in MetS 
compared to lean healthy subjects is due to an increase in CM and/or VLDL TAG 
production rate or a decrease in clearance rate. We hypothesised that an increased 
synthesis of both CM and VLDL TAG in MetS would be the major cause of the 
increased postprandial TAG. 
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Methods 
Participants 
This study was approved by the East Kent NHS Research Ethics Committee and 
University of Surrey Ethics Committee. Written informed consent was provided by all 
participants prior to inclusion in the study. Eight men with MetS and eight age 
matched lean healthy men were studied. MetS was defined as central obesity 
(increased waist circumference ≥ 94 cm) plus any two of the following four factors: 
triglycerides ≥ 1.7 mmol/L, HDL cholesterol <1.03 mmol/L, systolic BP ≥ 130 or 
diastolic BP ≥ 85 mm Hg or fasting plasma glucose ≥ 5.6 mmol/L. With the exception 
of one subject, all subjects could be defined as having MetS without using the BP 
criteria. This subject had raised waist circumference, raised blood glucose and plasma 
TG at screening was 1.65mmol/l.  All men had an apoE3E3 genotype. The exclusion 
criteria were a diagnosis of diabetes, hepatic and renal disorders, fasting plasma 
triglyceride >5mmol/L, cholesterol > 7 mmol/L, use of statins, fibrates or metformin. 
Experimental Design 
All subjects underwent an 11-hour feeding study after an overnight fast. Waist 
circumference was measured around the umbilicus. Body composition was measured 
using Tanita BC-418 Scales (Tokyo, Japan). An indwelling cannula was inserted into 
an antecubital vein for blood sampling.  Baseline samples were taken to measure the 
fasting lipid profile, glucose and insulin. All subjects were fed 6 high fat (83.3%; 23% 
saturated, 33% monounsaturated, 24% polyunsaturated fatty acids), low carbohydrate 
(12.2%) and low protein (4.5%) liquid meals, 497kcal per meal at two hourly intervals 
(at -240, 120, 0, 120, 240 and 360 minutes).  The aim of the feeding protocol was to 
increase fasting plasma TAG levels 2 fold and to maintain this for the duration of the 
study. This feeding protocol was successful at achieving steady state TAG levels. The 
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first 4 hours (-240-0 minutes) were to enable a TAG steady state to be achieved prior 
to administration of the tracers. The meal, composed of 125ml milk shake (Tesco, 
UK), 20ml double cream, 15ml olive oil and 20ml sunflower oil, was prepared as an 
emulsion.  Each unit meal was prepared immediately prior to consumption and 
consumed within 1 minute by the subject. Tripalmitate (13C3- glyceryl) (10mg/kgBW) 
was mixed with the 3rd meal administered at 0 min. An intravenous bolus of 750mg 
2H5-glycerol was also administered at 0 min.  Blood samples were then taken at 
intervals for 420 minutes for the measurement of plasma glycerol enrichment, 
Svedberg (Sf)>60 and Sf 20-60 lipoprotein TAG enrichment and concentration. 
 
Lipoprotein separation 
Lipoproteins were separated by sequential flotation ultracentrifugation to isolate 
Sf>60 (CMs and VLDL1), Sf 20-60 (CM remnants and VLDL2), in a fixed angle rotor 
50.4Ti (Beckman, USA) using a LE80-K ultracentrifuge (Beckman Coulter Optima, 
USA) as previously described (14).   
 
Isolation of endogenous and exogenous lipoproteins 
ApoB100 and apoB48 containing lipoproteins were separated using a sequential 
immunoaffinity binding method as previously described (14). Monoclonal antibodies 
to apoB100, 4G3, 5E11 and Bsol16 (Heart Institute, University of Ottawa, Canada) 
were coupled individually to protein G sepharose 4 Fast Flow (Amersham, UK) as 
previously described (14). After ultracentrifugation, lipoprotein fractions were loaded 
immediately onto the 4G3-matrix and incubated overnight.  Then after centrifugation 
to separate the unbound and bound lipoproteins, the supernatant was loaded on to the 
5E11-matrix, incubated at 4°C overnight, then centrifuged and the supernatant loaded 
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onto the Bsol16-matrix and incubated at 4°C overnight.  The unbound fraction 
(apoB48 containing lipoprotein) in the final Bsol16-matrix separation was separated 
by centrifugation.  The bound fractions from each separation on the 4G3-, 5E11- and 
Bsol16- matrices (apoB100 containing lipoproteins) were combined. 
 
Measurement of lipid and hormone concentrations  
Enzymatic assays were used to measure fasting and fed plasma NEFA, total 
cholesterol, plasma TAG, the total fraction TAG (Sf>60 and Sf 20-60) and the CM 
fraction TAG (Sf>60 and Sf 20-60) (ABX, Chicksands, Shefford, Bedfordshire, UK) 
using a Cobas MIRA (Roche, Welwyn Garden City, UK). The CM fraction TAG was 
concentrated 7 fold prior to measurement. VLDL1 TAG concentration was calculated 
as the difference between the total Sf>60 TAG concentration (measured prior to 
antibody separation) and the Sf>60 CM TAG concentration. VLDL2 TAG was 
calculated as the difference between the total Sf 20-60 TAG concentration and the Sf 
20-60 CM TAG concentration. HDL-cholesterol was measured on a Bayer Advia 
1650 analyzer (Bayer, Newbury, United Kingdom). Insulin, adiponectin, and leptin, 
were measured by immunoassay using commercially available kits (Millipore 
corporation, Billerica, MA, USA). 
 
Isotopic enrichment determination 
TAG in the lipoprotein fractions isolated by immunoaffinity chromatography was 
extracted in chloroform: methanol (2:1, vol%) and separated by thin-layer 
chromatography, then hydrolysed with 3%HCl in methanol (vol%) at 50°C overnight.  
Glycerol was then purified by ion-exchange chromatography and concentrated by 
freeze-drying overnight (15). For analysis of plasma free glycerol, samples (0.5ml) 
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were deproteinised and purified by ion-exchange chromatography.  Freeze-dried 
glycerol was derivatised to glycerol triacetate (15), and enrichment measured by gas 
chromatography mass spectrometry (GC-MS) in PCI mode with methane as the 
reagent gas.   Ions were monitored at m/z 159 and at m/z 164 (m+5).  Enrichment of 
the CM remnants (Sf 12-20) with 2H5-glycerol was below the detection limit of the 
assay in most participants. 
 The  13C/12C isotope ratio determination of oral glycerol tracer was performed with a 
Trace GC Ultra with auto sampler AS3000, coupled to an isotope ratio mass 
spectrometer Delta Plus XP (Thermo Electron, Corp, USA) via an oxidation reactor, 
reactor temperature 960oC and a combustion interface III (Thermo Electron 
Corporation, Bremen, Germany).  Enrichment of the CM remnants (Sf 12-20) with 
13C-glycerol was below the detection limit of the assay in most participants. 
 
 
Data analysis 
VLDL1, VLDL2 and CM TAG kinetics were calculated using a mathematical model 
as previously described (14). A single pool model was used to describe CM TAG 
kinetics and a two pool model to describe VLDL1 and VLDL2 TAG kinetics using 
the SAAM II program (SAAM Institute, Seattle, WA). The models represent the 
kinetics of the tracer-to-tracee ratio (TTR) profiles which change as labelled glycerol 
is removed from plasma and incorporated into the TAG fractions. The models 
included a delay pathway for the incorporation of glycerol into VLDL TAG by the 
liver and CM TAG in the intestine. The VLDL TAG model included a compartment 
for VLDL1-TAG and a compartment for VLDL2-TAG with an input into both 
compartments from the glycerol precursor pool, a loss from each compartment and a 
9 
 
transfer from the VLDL1-TAG compartment to the VLDL2-TAG compartment. In a 
steady state, the fractional secretion rate (FSR) is equal to the fractional catabolic rate 
(FCR), a measure of clearance. The production rate was calculated from the product 
of the FSR and the TAG pool size. TAG pool size was calculated from the TAG 
concentration of the bound and unbound fraction multiplied by plasma volume. 
Plasma volume was calculated as described by Pearson et al (16). Fasting insulin 
sensitivity was assessed by homeostatic model assessment (HOMA-IR) (17). 
 
 
Statistical analysis  
Results are presented as mean±SEM.  Data were analysed using SPSS 16 (SPSS inc; 
Chicago USA).  Non-parametric data were logarithmically transformed before 
statistical analysis.  Analysis of concentrations during frequent feeding was by 
repeated measures ANOVA.  The increment in plasma TAG from fasting to feeding 
was calculated as the difference between the mean TAG during frequent feeding and 
fasting plasma TAG. Comparison of measurements in the two groups was by unpaired 
two-tailed t-test.  A P value lower than 0.05 was considered to be significant. 
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Results 
Body composition, insulin sensitivity and fasting lipid profile (Table 1) 
Body weight, BMI, waist circumference and fat mass were higher in the men with 
MetS than the healthy lean men (all p<0.001). Fat free mass was not different 
between groups. Glucose and insulin concentration and HOMA-IR were higher in 
MetS (p=0.01, p=0.05, p=0.03). Fasting plasma TAG was higher and HDL cholesterol 
was lower (p=0.04, p<0.04) but plasma cholesterol, and NEFAs were not significantly 
different in MetS.  
 
Prandial concentrations 
Plasma TAG, NEFA, glucose and insulin during frequent feeding are shown in Figure 
1. Plasma TAG, Sf>60 TAG and Sf 20-60 TAG were not significantly different 
between 0 and 420 minutes in either group. During feeding mean plasma TAG, 
plasma glucose and serum insulin were significantly higher in the men with MetS 
compared with the lean men (p=0.03, p=0.01, p=0.05 respectively). The increment in 
plasma TAG from fasting to frequent feeding was also higher in the men with MetS 
(2.94±0.87 mmol/l) than in the lean men (0.88±0.19 mmol/l) (p=0.04). Plasma NEFA 
concentration did not differ between the 2 groups during feeding.  
 
CM enrichment profile with the oral 13C-glycerol tracer 
The enrichment of the 13C glycerol tracer in the CM and VLDL1 TAG is shown in 
Figure 2. The AUC for CM TAG enrichment was not different in the two groups. 13C 
glycerol enrichment in VLDL1 TAG was <8% of CM enrichment 150 minutes after 
tracer administration in the lean men demonstrating that the immnoaffinity method 
was efficiently separating the CM and VLDL fractions.  There was a small rise in 
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enrichment of VLDL1 TAG with 13C glycerol during the remainder of the study. In 
the men with MetS, 13C glycerol tracer enrichment in VLDL1 TAG, measured as 
AUC, was higher than in the lean men (p=0.05).  
 
VLDL and CM kinetics (measured with an intravenous 2H5-glycerol tracer) 
Plasma glycerol enrichment was not different in the 2 groups (data not shown). The 
enrichment of CM TAG, VLDL1 and VLDL2 TAG, with the iv tracer, 2H5-glycerol, 
in the lean men and men with MetS is shown in figure 3, figure 4a and 4b respectively. 
In the men with MetS CM, VLDL1 and VLDL2 TAG production rates were higher 
(p<0.002, p<0.05, p=0.057) (Figure 5) and CM, VLDL1 and VLDL2 TAG pool sizes 
were higher (p=0.006, p=0.03, p<0.02) than in the lean men. There was no significant 
difference between the 2 groups in VLDL1, VLDL2 and CM TAG FCR, a measure of 
clearance. 
  
Discussion  
In men with MetS the increment in plasma TAG in response to frequent feeding was 
considerably higher than in age matched healthy subjects despite both groups 
receiving identical meals. The higher fed TAG level in MetS was due to a higher 
production rate of VLDL1, VLDL2 and CM TAG rather than reduced clearance. 
Previous studies have shown that prandial VLDL and CM particle production rate, 
measured by tracer labelling of apolipoproteinB100 and B48 respectively, is increased 
in insulin resistant subjects (18, 8). However these studies did not measure the 
kinetics of the TAG substrate within the particle. In the present study we show for the 
first time that prandial VLDL and CM TAG production rate is increased using in vivo 
tracer labelling of TAG in MetS.   
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The oral tripalmitin tracer was labelled on the glyceryl moiety and previous studies 
suggest that approximately 75% of this would be absorbed as monoacylglycerol 
(MAG) and resynthesized into TAG with the remaining 25% being completely 
hydrolysed to glycerol and NEFA (19).  The amount of oral tracer administered was 
determined by body weight, so was 27% higher in the men with MetS. However the 
enrichment (tracer:tracee ratio) of CM TAG with this tracer was similar in the two 
groups demonstrating that there was greater dilution of this tracer with unlabelled 
TAG in the CM of men with MetS.  This suggests that more intestinal TAG were 
being exported in CM which was derived from a non-oral route in these subjects.   A 
greater production rate of CM TAG in MetS was confirmed from the kinetic 
measurements made using the 2H5 intravenous tracer. There are several possible 
sources of this non-oral TAG a) TAG synthesised from NEFA and glycerol imported 
from the circulation b) TAG synthesised from NEFA generated within the enterocyte 
from glucose (de novo lipogenesis; DNL) or c) the release of TAG or exchange of 
labelled MAG from the meal with unlabelled MAG, from pre-existing storage pools 
as shown in Figure 6.  
 
Previous studies have shown that an acute increase in NEFA levels in healthy subjects 
increases apoB48 production rate (20). Interestingly in the present study neither 
fasting nor prandial NEFA concentrations were different in the two groups suggesting 
this was not the driver for a higher synthesis rate of CM TAG in MetS. While the 
contribution of DNL to hepatic TAG synthesis is well known (21), it is only recently 
that this pathway has been demonstrated to be important in enterocytes, and in an 
insulin resistant hamster model enterocyte DNL was shown to be increased (9, 22). In 
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the liver DNL is an insulin- and glucose-dependent process under the control of 
specific transcription factors, sterol regulatory element binding protein 1c (SREBP-
1c), which is activated by insulin and carbohydrate response element binding protein 
(ChREBP) which is activated by glucose (23). ChREBP is also expressed in the small 
intestine and the elevated glucose in MetS may be responsible for an increase in DNL 
and CM TAG production rate.  
 
Both indirect and direct evidence exists supporting the presence of cytoplasmic TAG 
storage pools in enterocytes, so an elevated number or size of these pools in MetS 
may also be a contributing factor to the increased CM TAG export. Storage pools of 
TAG have been demonstrated in mice enterocytes and the TAG content was found to 
directly correlate with the amount of TAG consumed (24). In humans, sequential meal 
tests have shown that CMs secreted after a second meal carry TAG ingested in the 
first meal (25). Since mammalian enterocytes turn over every 3 to 4 days these can 
only be very short term stores (26). Higher food intake in the subjects with MetS 
could lead to larger TAG stores. To determine whether this source of TAG makes a 
major contribution to the elevated CM production rate, dietary intake would need to 
be fixed at the same level in the 2 groups of subjects for 3 days prior to the kinetic 
study. 
 
It has been clearly demonstrated that fasting VLDL TAG production rate is increased 
in insulin resistance (13). To the authors knowledge only one previous study has 
measured VLDL TAG production rate after feeding in insulin resistant subjects. In 
that study a constant infusion of ex vivo labelled VLDL TAG was used and VLDL-
TAG secretion rate was shown to be higher in men with type 2 diabetes than healthy 
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men (27). Although HOMA-IR was not reported in the latter study patients with type 
2 diabetes would be expected to be more insulin resistant then the subjects with MetS 
in the current study. The higher VLDL TAG production rate after feeding in MetS in 
the current study may be due to an increase in imported NEFA, DNL or TAG storage 
pools as discussed for the enterocyte. In addition the liver will take up recycled TAG 
from TRL including CM. The enrichment of VLDL1 TAG with 13C glycerol was very 
low initially but gradually increased with time indicating recycling of CM remnants to 
the liver as demonstrated previously (28). That this was higher in MetS is also 
supported by the study of Hodson et al (28) which showed 3.5 fold higher recycling of 
CM remnants in insulin resistant subjects compared to insulin sensitive subjects.  In 
non-alcoholic fatty liver disease, the hepatic manifestation of MetS, 15% of hepatic 
TAG was from the diet ie recycled  CM TAG, while DNL was shown to account for 
26% (29). However insulin resistance measured by HOMA-IR was considerably 
higher than in the subjects with MetS in the current study. Hepatic DNL has been 
shown to be increased in subjects with insulin resistance (30, 31) and has been 
directly linked to glucose and insulin levels (23). Fasting VLDL TAG production rate 
has also been shown to be correlated with hyperglycaemia (32).   
 
Insulin has been shown to suppress both apoB48 and apoB100 production rate during 
feeding in healthy subjects (33, 34) and this inhibitory effect is blunted in type 2 
diabetes (35). Fasting VLDL1 TAG production rate has also been shown to be 
inhibited by insulin with a reduced effect in insulin resistance (36). The increased CM 
and VLDL TAG production rate in the presence of elevated prandial insulin levels in 
the men with MetS also suggests an impaired effect of insulin. Impaired insulin 
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signalling has been demonstrated in enterocytes and hepatocytes from an insulin 
resistant animal model (22). 
While some previous studies have suggested that CM clearance is impaired in insulin 
resistance (7, 37) and thus responsible for the elevated postprandial TAG, CM TAG 
clearance rate was not different in the two groups in the current study.  This may be 
due to the different study design or less insulin resistance. In these previous studies (7, 
37) either a large oral fat load or an intravenous CM like emulsion was administered. 
TRL apoB48 FCR has been shown to be similar in healthy subjects and subjects with 
insulin resistance studied with a continuous feeding protocol (8). The mean half-life 
for CM TAG (Sf>60) in the current study can be calculated from the FCR to be 72 
minutes in the healthy subjects and 86 minutes in MetS. This is considerably longer 
than the half-life for CM TAG (Sf>400) previously reported to be 5-6 minutes in 
healthy subjects (38). In the density Sf>400, CM are approximately 340nm in 
diameter. In the Sf>60 density CM will include particles of this size but also particles 
as small as 40nm and this can explain the longer half-life. It has been reported that 
larger particles are cleared faster than smaller ones (39). The FCR for CM apoB48 in 
the density range Sf>20 has been reported to be 5.0 pools/day (a half-life of 200 
minutes) which is lower than in the current study, but a similar order of magnitude 
(40).  
The FCR for VLDL1 TAG in the two groups was in the range of previously reported 
measurements in fasting studies (32, 41). VLDL TAG clearance was not impaired in 
the fed state in MetS in the current study. This supports the findings of a single meal 
study in healthy men and men with type 2 diabetes which showed that although the 
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basal fasting FCR was lower in men with type 2 diabetes the postprandial FCR was 
not different in the 2 groups (27).  
A limitation of this study was that the percentage of fat in meal was considerably 
higher than would be expected in a physiological meal. Further studies need to be 
undertaken to confirm the findings of the study using a more physiological meal 
feeding protocol. 
In conclusion prandial hypertriglyceridemia in men with MetS was due to an 
increased production rate of both VLDL and CM TAG. Since both groups received 
identical meals this suggests that in MetS the intestine is synthesising more TAG de 
novo.  
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Table 1. Subject characteristics (mean±SEM) 
                                                 Lean              Met S 
 
P value 
Age (years) 59±2 57±2 NS 
Body weight (kg) 72.2±1.7 91.8±3.3 P<0.0001 
BMI 23.1±0.4 29.7±1.1 P<0.0001 
Waist (cm) 86.8±1.9 105.3±3.3 P=0.0003 
Fat mass (kg) 12.7±1.1 25.1±2.0 P=0.0001 
Fat Free Mass (kg) 59.5±1.6 65.9±3.3 NS 
Serum Insulin (pmol/l)      66.1±7.5 118.3±27.4 P=0.05 
Plasma Glucose (mmol/l) 5.0±0.3 5.8±0.1 P=0.01 
HOMA-IR 1.2±0.1 2.2±0.5 P=0.03 
Plasma 
Triglyceride(mmol/l)           
1.1±0.1 2.2±0.5 P=0.04 
Plasma Cholesterol 
(mmol/l)      
5.1±0.4 5.1±0.6 NS 
Plasma HDL Cholesterol 
(mmol/l) 
1.6±0.2 1.2±0.1 P<0.04 
Plasma NEFA (mmol/l) 0.43±0.06 0.53±0.05 NS 
Systolic BP (mmHg) 123.8±3.8 124.4±4.9* NS 
Diastolic BP (mmHg) 81.5±2.8 78.8±2.6* NS 
* 2 subjects were on anti-hypertensive medication 
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Figure legends 
Figure 1.  a) Plasma TAG  b) plasma NEFA c) plasma glucose and d) serum insulin in 
healthy subjects (○) and subjects with MetS (●) during frequent feeding (mean±
SEM).   
Figure 2.  13C3-glycerol enrichment in CM TAG (♦) and VLDL1 TAG (■) in a) 
healthy subjects and b) subjects with MetS (mean±SEM). 
Figure 3. 2H5 glycerol enrichment in CM in healthy subjects (○) and subjects with 
MetS (●) (mean±SEM). 
Figure 4. 2H5 glycerol enrichment in VLDL1 (♦) and VLDL2 TAG (■) in a) healthy 
subjects and b) subjects with MetS (mean±SEM).   
Figure 5. a) TAG PR b) TAG FCR and TAG pool size for VLDL1, VLDL2 and CM 
in healthy subjects (grey columns) and subjects with MetS (black columns) (mean±
SEM).  
Figure 6. Schematic of CM TAG synthesis in enterocytes showing labeling of TAG 
with oral 13C glycerol and intravenous 2H5 glycerol. A. TAG synthesis from dietary 
NEFA and MAG, B. TAG synthesis from endogenous (circulating) NEFA and 
glycerol, C. TAG synthesis from glycerol generated from glucose, D. TAG 
incorporation into CM from TAG stores. MAG (monoacylglycerol); CM 
(chylomicron); B48 (apolipoprotein B48); TAG (triacylglycerol) 
 
